Kenya introduced the monovalent Rotarix® rotavirus group A Background: (RVA) vaccine nationally in mid-2014. Long-term surveillance data is important prior to wide-scale vaccine use to assess the impact on disease and to investigate the occurrence of heterotypic strains arising through immune selection. This report presents baseline data on RVA genotype circulation patterns and intra-genotype genetic diversity over a 7-year period in the pre-vaccine era in Kilifi, Kenya, from 2002 to 2004 and from 2010 to 2013 A total of 745 RVA strains identified in children admitted with acute Methods: gastroenteritis to a referral hospital in Coastal Kenya, were sequenced using the di-deoxy sequencing method in the VP4 and VP7 genomic segments (encoding P and G proteins, respectively). Sequencing successfully generated 569 (76%) and 572 (77%) consensus sequences for the VP4 and VP7 genes respectively. G and P genotypes were determined by use of BLAST and the online RotaC v2 RVA classification tool.
Introduction
Rotavirus group A (RVA) infection is a leading cause of childhood severe dehydrating acute diarrhoea, which can lead to death 1 . The 2016 estimates show that, annually, RVA is responsible for 128,500 deaths globally, with the highest burden occurring in sub-Saharan Africa and South-East Asia countries 2 . In 2009, the World Health Organization (WHO) recommended the inclusion of either of the two licensed RVA vaccines (Rotarix® and RotaTeq®) into national immunization programmes (NIPs) of all countries to curb RVA associated disease burden 3 . Kenya introduced the monovalent Rotarix® vaccine (based on the G1P[8] strain) into its NIP in July 2014 4 .
In Africa, the introduction of the Rotarix® vaccine into the NIPs of several countries has been associated with a marked reduction in hospitalization caused by RVA infection 5, 6 . For instance in Malawi, Burkina Faso and Tanzania, the vaccine effectiveness against hospitalization was estimated at 62%, 58% and 53%, respectively 7 . However, this effectiveness is lower than that observed in developed countries; for example in Belgium, vaccine effectiveness of Rotarix vaccine was estimated at 90% 8 . Furthermore, concerns remain that in time, given the high diversity of RVA strains, vaccine immunity escape variants could emerge which may undermine the gains from the vaccination programmes 9 . Such a scenario was observed in Japan where, a G8P[8] RVA strain appeared to emerge and caused acute gastroenteritis disease in up to 66% (53/80) of children attending a pediatric clinic 10 . Similarly, the predominance of non-vaccine type G2P[4] strains was observed in Rotarix® vaccinated populations of Belgium 11 and Brazil 12 , raising concerns of the effect of the vaccine on circulating non-vaccine strains.
The rotavirus genome is comprised of 11 segments of double-stranded RNA, which encode 12 proteins (VP1-4, VP6, VP7, NSP1-6). The VP7 and VP4 proteins independently elicit neutralizing antibodies and specify the G (glycoprotein) and P (protease-sensitive) genotypes, respectively 13 . Molecular characterization of the VP7 and VP4 proteins encoding regions is commonly used to investigate local and global RVA molecular epidemiology and is the basis of the dual genotype classification of this virus 14 . Up to 36 different G and 51 P RVA genotypes have been identified worldwide in humans and animals 15 .
Globally, G1P[8], G2P[4], G3P[8], G4P[8] and G9P
[8] (in decreasing order) have been identified as the most common genotypes causing disease in children, although their distribution can vary considerably from region to region and from one season to the next 16, 17 . While these genotypes are similarly dominant in Africa 18 , understanding of their local natural seasonal fluctuations and intra-genotype diversity in the pre-vaccine introduction era is incomplete despite importance to vaccine impact evaluation.
The current study presents molecular analysis of historical RVA strains from coastal Kenya detected between 2002-2004, reported in Nokes et al.
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, which we refer to as phase 1, together with more recent RVA strains detected between 2010-2013, referred to as phase II. We present findings from partial sequence analysis of these longitudinally collected RVA strains identified at the Kilifi County Hospital (KCH), Kilifi, Kenya, and phylogenetically compare these with those deposited in public databases across the globe. The typing of phase I strains was previously performed by nested multiplex PCR using genotype-specific VP7 and VP4 primers 19 . We utilize these extensive sequence data to illuminate on local RVA genotype circulation characteristics and provide baseline information on natural patterns of RVA genotype diversity in coastal Kenya prior to vaccine introduction.
Methods

RVA surveillance in Kilifi County Hospital
RVA surveillance in KCH reported in this analysis was conducted from January 2002 to December 2004, and from January 2010 to December 2013. Study subject recruitment criteria and sample collection methods are as previously described 19 . The study targeted children aged less than 13 years admitted with acute diarrhoea defined as three or more watery stools passed during a 24-hour period 20 . The KEMRI Scientific and Ethics Review Unit (SERU) in Kenya approved the study protocol.
Detection of RVA Stool samples were screened for RVA using an enzyme immunoassay (EIA) kit, marketed under two different names in the two periods: IDEIA (DAKO Rotavirus IDEIA TM , Oxoid, Ely, United Kingdom) in phase I and ProSpect TM (Oxoid, Basingstoke UK) in phase II, following the manufacturer's instructions.
Partial sequencing of RVA positive samples in VP4 and VP7 segments Sequencing was conducted on 272 (46%) of 558 positive samples detected in phase I, and all positive samples identified in phase II (n=473). The phase I samples were selected to represent common RVA genotypes (>70%) observed throughout the surveillance period from each year. Partial fragments of the VP4 and VP7 genes, were amplified in a one-step reverse transcriptase PCR reaction using the following primer pairs: VP4F, 5'-TAT-GCTCCAGTNAATTGG-3', VP4R 5'-ATTGCATTTCTTTC-CATAATG-3', VP7F, 5'-ATGTATGGTATTGAATATACCAC-3', VP7R 5'--AACTTGCCACCATTTTTTCC-3', as previously described by Simmonds et al. 21 and Gomara et al. 22 . To confirm successful amplification of the targeted genomic area the products were checked (VP7, 881 bp; VP4, 660 bp) by electrophoresis in a 2% agarose gel. Products of samples that showed presence of the expected band size on gels were purified using GFX DNA purification kit (GFX-Amersham, UK) following the manufacturer's instructions. These were then sequenced using Big Dye Terminator 3.1 (Applied Biosystems, Foster City, California, USA) chemistry and the same primers as in PCR amplification on an ABI Prism 3130xl Genetic Analyser (Applied Biosystems, Foster City, California, USA).
RVA genotyping and sequence analysis
The sequence reads were assembled into contigs using Sequencher version 5.4.6 (Gene Codes Corp Inc., Ann Arbor, MI, USA). The nucleotide sequences were aligned using MAFFT version 7.222 23 and visualized in Aliview version 1.8 and further trimmed to remove sequence overhangs, resulting in contigs of lengths between 480-660 bp (coordinates; 184-748) covering ~23% of the VP4 gene, and 486-854 bp (coordinates; 460-824 of the VP7 gene) covering ~67% of the VP7 gene. G and P genotypes were determined using NCBI BLAST for sequences <500 bp (n=13 for VP4, n=5 for VP7) and the RotaC version 2.0 classification tool 24 for sequences >500 bp. MEGA v7.0.26 was used to select the best maximum likelihood evolution models based on the Bayesian Information Criterion 25 (Supplementary Table 1 ) and reconstruction of maximum likelihood phylogenetic trees with 500 bootstrap replicates. Global contemporaneous sequences (2002-2013) (accession numbers in Supplementary File 1, lists 1 and 2) together with the Rotarix® vaccine strain sequences were retrieved from GenBank database and phylogenetically compared with the local sequences. Duplicate sequences from the same country and non-overlapping sequences were removed. Clusters were identified based on high bootstrap values of >70% and high nt sequence similarity of >98%. Nucleotide and amino acid pairwise distances between the sequences were determined in MEGA v7.0.26. The trees were drawn to scale indicating nucleotide substitution rates per site.
Results
The prevalence of the genotypes and the circulation patterns described in this study were determined by use of all the data collected RVA prevalence in KCH pediatric diarrhoea admissions Over the 7-year surveillance period, a total of 3,779 stool samples were screened for RVA using EIA, of which 27.3% (n=1,031) tested positive. In phase I, the prevalence of RVA in the study population was 27.4% (n=558) while in phase II the prevalence was 27.2% (n=473) ( Table 1) . Sequencing was successful for 569 (76%) and 572 (77%) samples for the VP4 and VP7 segments respectively (Table 1) .
RVA genotypes in the study populations The G genotypes identified in patients admitted at the KCH were G1-G3, G8-G10, G12, G29, while the P genotypes were P The previous use of genotype-specific primers (rather than sequencing) to identify RVA strains in phase I enabled the detection of mixed infections in 8.2% of the cases; however, mixed infections were not seen when using sequence based methods. Additionally, 9.2% of the samples were typed for only one of the two genes due to failure in sequencing and/or contig assembly (Table 2) . Majority of the G8 strains showed high sequence homology of 96-100%, forming a common cluster including strains from both phases. However, a single sequence showed a decrease in homology up to 84% at nt level, and formed distinct clusters. The infrequently occurring G2 strains, formed two distinct clusters, where one cluster contained strains observed in phase II while the other had strains from both phases. Nevertheless, a high sequence homology of >95% at the nucleotide level was observed within G2 strains. Such high sequence homology was also observed in G9 strains, which were observed in high frequencies in all epidemic years except 2013. Figure 3 and Figure 4 . Tree clusters leading to Kilifi strains are . We therefore sought to investigate the probable origin of the observed G8P[14] detected in a 14 months old infant in 2010. All cognate sequences for genotypes G8 (n=71) and P[14] (n=47) isolated by 2013 were retrieved from GenBank and phylogenetically compared to the observed genotypes. Duplicate sequences from strains isolated from the same country were removed. The G type in this samples (G8) clustered closely to other G8 strains isolated from humans with a nucleotide and amino acid (aa) identity of 95% and 99%, respectively, and G8 strains isolated from camel showing a nucleotide and aa identity of 94% and 98%, respectively ( Figure 5A ). The P[14] genotype showed a high sequence similarity to other P[14] strains isolated from humans and bovine with a nucleotide similarity of 96% and 93% respectively and aa identity of 98% ( Figure 5B ).
Discussion
The present study provides insight into the molecular epidemiology and phylogenetic relatedness of distant (7 years or more) and recent pre-vaccine introduction RVA strains detected in Kilifi, Coastal Kenya. This is the first detailed study on prevalence of RVA genotypes causing diarrhoea in children in rural coastal Kenya spanning over a decade before introduction of the nationwide routine RVA vaccination programme. The work builds on a previous study 19 , which highlighted the importance of genotypes G1, G8 and G9 in sub-Saharan Africa during the pre-vaccine introduction period. During phase I surveillance period, genotype-specific primers were used to characterize the strains into different G and P genotypes. In the present analysis, a fraction of phase I (46%) and all phase II RVA samples were sequenced and GP annotations assigned as per the guidelines of the Rotavirus Classification Working Group 26, 38 . In this study, the close association of the observed strain G8P[14] with strains from both humans and animal origins shows a possibility of zoonotic transmission. The increase in diversity of RVA in this setting could be attributed to the emergence of such unusual strains which might have arisen due to zoonotic transmission or re-assortment cases within and between RVA genotypes.
Post-vaccine surveillance studies have reported shifts in the prevalence of RVA genotypes. Recent post-vaccine introduction reports from Kenya have indicated an increase in prevalence of uncommon genotypes G3, G9 and G12
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. Similarly, data from the USA depicted an increase in prevalence of G3P [8] in post-vaccine era relative to G1P [8] in the pre-vaccine period. In contrast, surveillance studies in Australia and Belgium revealed the dominance of G2 strains in post-vaccine period, relative to G1P[8] in pre-vaccine period. Similar studies in Ghana reported an increase in prevalence of G12P[8] and G10P [6] in the post-vaccine era. This shift in distribution of genotypes post-vaccine introduction might be associated with either selective vaccine pressure or the natural fluctuations of RVAs, although these are not evidently supported. The emergence of uncommon genotypes and increased prevalence of non-vaccine strains warrants close monitoring to determine their circulation in the post-vaccine introduction period and their probable effect on performance of the vaccine.
Overall, the observed strains showed a high nucleotide sequence homology of up to 100%, as observed in the different genotypes. The close genetic relationship of strains observed in phase I and phase II suggest a persistence in circulation of these RVA strains to continuously cause the observed epidemics. In addition, the exclusive clustering of majority of Kilifi strains from the global strains shows that theses strains might have been localized in Kilifi over a long period of time. However, few strains that formed three distinct clusters in both G1 and P[8] global trees, supports the notion of separate introductions and persistence of possibly foreign strains in this setting. Although cases of re-assortment and possible introductions is evident, partial data from only two genes is insufficient in providing a complete understanding of the genetic diversity of such common and not common genotypes. Full genome sequencing will thus illuminate on the complete genomic constellations of these strains and provide data on their evolutionary dynamics. The marked seasonal and longer-term changes in genotype distribution observed in this pre-vaccine surveillance should be considered when interpreting changes to genotype patterns that may follow the introduction of rotavirus vaccine in any setting.
This study had several limitations, e.g. firstly, by use of partial sequencing method, we were unable to identify mixed infections in phase II, which were previously identified in phase I using other primer-based methods. Partial sequencing only identifies the dominant genotype in mixed infections resulting to one genotype. The sequencing chromatograms of samples identified as mixed infections in phase I, appeared clean and mono-infected, with no background indicators of co-infections. Secondly, the classification of the strains into lineages and sub-lineages was limited due to the short consensus sequences, since only ~23% and ~67% of the VP4 and VP7 genes were sequenced, respectively. Thirdly, it was not possible to perform comparative analysis of the rare genotype G29 due to unavailability of cognate sequences in GenBank. Only a single reference sequence for genotype G29 had been deposited in GenBank by the time of this analysis.
In conclusion, this study shows that most of the pre-vaccine RVA infections and epidemics have been caused by a diverse range of RVA strains which fluctuated in prevalence from season to season, with some persistent in circulation for a long period. Additionally, new strains might have been introduced in this population and contributed significantly to the epidemics experienced in the pre-vaccine period. The recommendation by WHO for countries to vaccinate infants against rotavirus infection led to the inclusion of Rotarix TM vaccine in the childhood immunization programme in Kenya. In addition to reducing hospitalization caused by RVA diarrhoea, the vaccine has been reported to offer protection against both homotypic and heterotypic RVA strains 9 . With the increase in diversity of circulating strains and emergence of rare strains in Kilifi, continuous monitoring will help evaluate the performance of this vaccine against the circulating strains.
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